The lancet. Diabetes & endocrinology
-
Lancet Diabetes Endocrinol · Sep 2018
Randomized Controlled Trial Multicenter StudyCanagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.
In the Canagliflozin Cardiovascular Assessment Study (CANVAS) Program, canagliflozin reduced the rates of major adverse cardiovascular events and the results suggested a renal benefit in patients with type 2 diabetes who were at high risk for cardiovascular events, compared with those treated with placebo. Here we report the results of a prespecified exploratory analysis of the long-term effects of canagliflozin on a range of sustained and adjudicated renal outcomes. ⋯ Janssen Research & Development.